HIV inhibitors: problems and reality

Area of Science:

• Virology
• Pharmacology
• Immunology

Background:

• Human immunodeficiency virus (HIV) requires three replication enzymes for its lifecycle.
• Current antiretroviral therapies, including highly active antiretroviral therapy (HAART), suppress HIV but do not eradicate it.
• Long-term HIV therapy necessitates continuous drug use, leading to challenges.

Purpose of the Study:

• To address the limitations of current HIV therapies.
• To explore the development of new antiretroviral drugs.
• To identify compounds effective against drug-resistant HIV variants and with reduced side effects.

Main Methods:

• Review of current antiretroviral drugs and their mechanisms of action (reverse transcriptase and protease inhibitors).
• Analysis of the challenges associated with long-term HIV treatment, including drug resistance and adverse effects.
• Identification of the need for novel drug development.

Main Results:

• Current HIV inhibitors face limitations due to the rapid development of drug-resistant variants.
• Long-term use of antiretroviral drugs is associated with various side effects, including hypersensitivity, mitochondrial toxicity, lipodystrophy syndrome, insulin resistance, and cardiovascular disorders.
• Existing therapies suppress viral load but do not achieve eradication.

Conclusions:

• Further drug development is crucial for managing HIV infection.
• New compounds are needed with efficacy against resistant HIV strains.
• Novel antiretroviral agents should aim to minimize unwanted metabolic side effects observed with current treatments.